EMA — authorised 25 July 2013
- Marketing authorisation holder: Sicor Biotech UAB
- Status: approved
🇪🇺 Lonquex in European Union
EMA authorised Lonquex on 25 July 2013
Marketing authorisations
EMA — authorised 25 July 2013
- Application: EMEA/H/C/002556
- Marketing authorisation holder: Teva B.V.
- Local brand name: Lonquex
- Indication: Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
- Status: approved
Lonquex in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in European Union
Frequently asked questions
Is Lonquex approved in European Union?
Yes. EMA authorised it on 25 July 2013; EMA authorised it on 25 July 2013.
Who is the marketing authorisation holder for Lonquex in European Union?
Sicor Biotech UAB holds the EU marketing authorisation.